Clinical bottom line
Tumor-infiltrating B cells (TIL-Bs) represent a promising but underappreciated component of the tumor immune microenvironment with emerging evidence suggesting their potential role in modulating immunotherapy response and prognosis across various solid tumors. Current data indicate that higher densities of TIL-Bs are often associated with improved survival outcomes and may enhance the efficacy of immune checkpoint inhibitors, particularly in non-small cell lung cancer (NSCLC). However, the functional heterogeneity of TIL-Bs and their complex interactions within the tumor milieu warrant cautious interpretation. While TIL-Bs could become valuable biomarkers or therapeutic targets, their integration into clinical decision-making remains investigational and requires further validation.
What the evidence shows
A recent systematic review and meta-analysis by Liu et al. (2023) evaluated the prognostic impact of tumor-infiltrating B lymphocytes across multiple solid malignancies. Their analysis demonstrated that elevated TIL-B levels correlated with significantly better overall survival and progression-free survival in several cancer types, suggesting a broadly favorable prognostic role. This meta-analysis highlights the consistency of TIL-Bs as a positive prognostic marker but also notes variability depending on tumor histology and microenvironmental context.
Focusing on NSCLC, Qiu et al. (2026) provided a detailed review of TIL-B biology and clinical implications. They reported that TIL-Bs contribute to antitumor immunity through antigen presentation, antibody production, and formation of tertiary lymphoid structures, which are linked to improved responses to immune checkpoint blockade. Their work underscores that TIL-B abundance and functional state may predict immunotherapy outcomes, positioning TIL-Bs as candidate biomarkers for patient stratification.
At the molecular level, Stoler-Barak et al. (2025) analyzed B cell immunoglobulin repertoires derived from cancer patients, revealing that tumor-infiltrating B cells can produce tumor-reactive antibodies, suggesting a direct role in tumor recognition and immune activation. This supports the hypothesis that TIL-Bs are not merely bystanders but active participants in antitumor immunity.
Additional mechanistic insights come from studies on immune cell interactions within the tumor microenvironment. Jacquin et al. (2020) discussed how autophagy influences tumor-infiltrating immune cells, including B cells, affecting their survival and function, which may indirectly impact immunotherapy efficacy. These cellular pathways represent potential targets to modulate TIL-B activity therapeutically.
Caveats and uncertainty
Despite promising associations, the role of TIL-Bs is complex and context-dependent. The heterogeneity of B cell subsets within tumors—ranging from regulatory B cells that may suppress immunity to plasma cells producing antibodies—complicates interpretation of their net effect. Most clinical data remain correlative, and causal mechanisms linking TIL-Bs to treatment response are incompletely understood.
Furthermore, the spatial distribution of TIL-Bs, their interaction with other immune cells, and the influence of tumor-intrinsic factors are not fully characterized. Variability in detection methods and thresholds for defining “high” versus “low” TIL-B infiltration across studies limits standardization.
Clinical studies specifically evaluating TIL-Bs as predictive biomarkers for immunotherapy response are limited, with most evidence derived from retrospective analyses or small cohorts. Prospective validation and integration with other immune parameters are needed before clinical application.
How this may change practice
Recognition of TIL-Bs as contributors to antitumor immunity may prompt incorporation of B cell assessment into tumor immune profiling panels in research and eventually clinical settings. This could refine patient selection for immunotherapies, especially in cancers like NSCLC where TIL-Bs appear most relevant.
Therapeutically, strategies to enhance beneficial TIL-B functions or modulate suppressive subsets may emerge as adjuncts to checkpoint inhibitors. For example, agents targeting B cell survival pathways or promoting tertiary lymphoid structure formation could synergize with existing immunotherapies.
Clinicians should remain aware of the evolving evidence and consider participation in clinical trials investigating TIL-B–targeted approaches or biomarker-driven immunotherapy strategies. Routine clinical use of TIL-B metrics is premature but represents a promising frontier in personalized oncology.